A phase I, placebo-controlled, randomised, crossover, bioequivalence trial of sublingual and injectable formulations of apomorphine.
Latest Information Update: 27 Jun 2015
At a glance
- Drugs Apomorphine (Primary) ; Apomorphine (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- 25 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders (MDS), according to a Cynapsus Therapeutics media release.
- 25 Jun 2015 Results published in a Cynapsus Therapeutics media release.
- 18 Jun 2015 Results presented at the 19th International Congress of Parkinson's Disease and Movement Disorders.